The clinical-stage pharmaceutical company SOM Biotech, focused in repositioning drugs in orphan CNS indications, has just closed a €2M euros financing round led by investor from a Monaco based private investment firm.

PRESS RELEASE (English)

SUBCRIBE TO OUR NEWSLETTER

    Name*
    Email*


    I confirm that by completing this form I have used only personal data about myself and that they are true and up-to-date.
    SOM INNOVATION BIOTECH, S.A. is responsible for the processing of my personal data to manage the newsletter service requested through the form, as well as to track the receipt of these through tracking technologies. The Privacy Policy tells me how I can exercise my rights of access, rectification, deletion, limitation, portability and opposition.